#OurStoriesOurMission
While planning activities for breast cancer awareness month at COTA, Helena Yelovich who works on our medical team, made an impassioned request: “Don’t Ignore Stage 4.” Read more about her story on our blog.
Celebrating Diversity with COTA
Did you know COTA has a Diversity & Inclusion Committee to foster conversation, collaboration, and education between employees? Learn more about how this group recently celebrated National Celebrate Diversity Month and Pride Month, as well as COTA’s support of the Title VII amicus brief.
STAT+: How to Apply Real-World Evidence to Outsmart Cancer
Elaborating on the use cases for real-world data, Chris Boone, VP for global medical epidemiology & big data analysis at Pfizer, and Viraj Narayanan, VP of life sciences at COTA, Inc., recently co-authored a STAT+ article that explores how real-world evidence can be used to fuel precision medicine and disrupt increasingly outdated clinical trial models.
ASCO 2019 – The Reaffirmation of Real-World Evidence in Cancer Care
The CO10s are back from ASCO 2019! See what Mike Doyle, COTA’s CEO, took away from this year’s conference as it relates to the use of real-world data and evidence in cancer care.
COTA News – Multiple Myeloma Research Foundation Launches CureCloud™ to Advance Precision Medicine
The MMRF announced they are launching CureCloud™, a centralized data hub that generates, aggregates and visualizes data to advance precision medicine to patients living with multiple myeloma. See how COTA is supporting this program!
COTA Team Member Spotlight: CC Obi-Gwacham
Learn more about CC Obi-Gwacham in the latest COTA Team Member Spotlight!
ASCO 2019 – How Precision Medicine and RWE Can Shape the Future of Oncology Care
In advance of the 2019 ASCO Annual Meeting, members of COTA’s medical leadership team offer predictions for this year’s conference on topics including the role of precision medicine and RWE in oncology care.
COTA Team Member Spotlight: Emily Di Capua
As a company that builds solutions that analyze real-world data to deliver clinically relevant insights that improve cancer care, we want to step back and feature the wonderful COTA team members (called CO10s) who are helping us achieve this goal. This week, we’re featuring Emily Di Capua, our VP of Strategic Initiatives.
The FDA’s History with RWE – and Continued Momentum from Dr. Sharpless
Earlier this month, Dr. Scott Gottlieb, the popular FDA Commissioner, announced he is resigning. COTA’s blog explores what this means for the future of RWE and the FDA.
Reevaluating Expectations for HIT’s Biggest Bonanza
COTA’s CEO Mike Doyle highlights his key takeaways from HIMSS19 around data stockpiling, thinking like consumers, and precision medicine.
